US Stock MarketDetailed Quotes

NMRA Neumora Therapeutics

Watchlist
  • 1.970
  • -8.630-81.42%
Close Jan 2 16:00 ET
  • 2.040
  • +0.070+3.55%
Post 19:20 ET
318.28MMarket Cap1.77P/E (TTM)

Neumora Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Neumora Therapeutics Q3 2024 Earnings Date

Currency：USDNov 12, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
EPS
-0.39
-0.45
-0.06
Miss Est.
+65.78%
+60.53%
-15.36%
Net Income
--
-72.55M
--
-36.81%
Analyst Rating
Strong Buy

Jan 2, 2025

Neumora Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 12, 20242024/Q30.000 / 0.000--
--2024/Q20.000 / 0.000--
--2024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 12, 20242024/Q30.000 / 0.000--
--2024/Q20.000 / 0.000--
--2024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Neumora Therapeutics Earnings Reports

  • Neumora Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 12, 2024 16:24 ET

  • Neumora Therapeutics | 8-K: Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

    Nov 12, 2024 09:31 ET

  • Neumora Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 6, 2024 16:07 ET

  • Neumora Therapeutics | 8-K: Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

    Aug 6, 2024 07:19 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jan 2, 2025

    Strong Buy

    • Buy

      85.71%

    • Hold

      14.29%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data